IL6 and neoplasm: No clinical studies have been performed which examine the clinical utility of IL-6 or IL-6 receptor antibodies in a breast cancer setting; however, given the promising results from trials in other tumor streams, there is a clear potential for examining the antibody blockade for breast cancer patients.